Diffuse large B-cell lymphoma in the very elderly: The case for refining our clinical trials

摘要

As life expectancy and the number of geriatric patients continue to rise, the incidence of diffuse, large B-cell lymphoma (DLBCI.) in the elderly will undoubtedly continue to increase as well. A limited understanding of the disease palhogenesis and lack of screening further suggest that preventative strategies are unlikely to slow this rate in the near future and that more eilicacious and less toxic treatment regimens will be needed.